<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Optic neuropathies
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Optic neuropathies
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Optic neuropathies
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Benjamin Osborne, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Laura J Balcer, MD, MSCE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Paul W Brazis, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Janet L Wilterdink, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 23, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optic nerve carries the greater than one million axons that derive from the retinal ganglion cells and project to eight visual nuclei. Actually an extension or tract of the central nervous system, not a true peripheral nerve, the conventional designation of the optic nerve applies to that portion of this tract that extends from the eye to the optic chiasm.
        </p>
        <p>
         This topic will review functional anatomy of the optic nerve and the differential diagnosis of optic nerve pathologies. Specific disorders are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">
          "Optic neuritis: Pathophysiology, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5256.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ANATOMY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optic nerve has four anatomic segments: the intraocular, intraorbital, intracanalicular, and intracranial sections [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The intraocular portion, or the optic disc, consists of the unmyelinated retinal ganglion cell axons and astrocytes. As the nerve exits the globe, crossing the collagenous lamina cribrosa, it increases in diameter as it becomes myelinated by oligodendrocytes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The intraorbital segment of the optic nerve is approximately 25 to 30 mm. Within the orbital apex, the optic nerve is surrounded by dura, arachnoid, and pia mater. The subarachnoid space contains cerebrospinal fluid (CSF) continuous with that of the brain and spinal cord. The dural covering fuses with the sclera around the optic nerve and more posteriorly with the periosteum of the optic canal. The nerve courses through the annulus of Zinn, which contains the connective tissue origins of the superior, medial, lateral, and inferior rectus muscles.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The nerve then passes through the optic foramen into the bony optic canal, which lies posteromedially in the lesser wing of the sphenoid bone, and is approximately 4 to 10 mm in length. The ophthalmic artery and ocular sympathetic nerve fibers also travel through the optic canal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intracranially, the optic nerve courses medially and rises at an angle of 45 degrees toward the chiasm. This segment of the optic nerve is approximately 16 mm in length and lies superior to the cavernous sinus and inferior to the frontal lobe and anterior cerebral and anterior communicating arteries.
        </p>
        <p>
        </p>
        <p>
         The blood supply of the optic disc and nerve is distinct from that of the retina, which is supplied by the central retinal artery. The disc is supplied by anastomosing arterioles supplied by the posterior ciliary arteries, the pial arteriole plexus, and the peripapillary choroid. The intraorbital segment receives blood from perforating branches of the ophthalmic artery, while the intracanalicular and intracranial portions are supplied by pial branches of the ophthalmic, internal carotid, anterior cerebral, and anterior communicating arteries.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic nerve lesions usually produce monocular visual loss. Pain is a variable feature that, when present, suggests optic nerve disease. Other features common to optic neuropathy include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Afferent pupillary defect if the lesion is unilateral or asymmetric
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Central vision loss (scotoma) on visual field testing
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dyschromatopsia often out of proportion to acuity loss
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Papillitis on funduscopic examination if the optic disc is involved  (
         <a class="graphic graphic_picture graphicRef66013" href="/z/d/graphic/66013.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef50320" href="/z/d/graphic/50320.html" rel="external">
          picture 2
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eventual optic atrophy
        </p>
        <p>
        </p>
        <p>
         The clinical presentation varies with etiology. Many are acute, but some etiologies are associated with a more subacute or even a chronic progressive course. Ophthalmologic examination and magnetic resonance imaging (MRI) of the brain and orbits are often essential to the diagnosis. In other cases, lumbar puncture with spinal fluid examination and other tests are required.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          ETIOLOGIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic neuritis is the most common cause of optic nerve disease in younger adults, while ischemic optic neuropathy is the most common etiology in older patients. The clinical features of the more common optic neuropathies are summarized in the tables  (
         <a class="graphic graphic_table graphicRef75945" href="/z/d/graphic/75945.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef51786" href="/z/d/graphic/51786.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Ischemic optic neuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ischemic optic neuropathy is more common in patients over age 50. Ischemic optic neuropathy is generally categorized as anterior (affecting the optic disc) versus posterior (retrobulbar) and as arteritic versus nonarteritic. Anterior involvement is usual with both arteritic and nonarteritic ischemic optic neuropathy (AION and NAION). Posterior ischemic optic neuropathy (PION) can also be due to either arteritic or nonarteritic etiologies, but should raise the suspicion of arteritis [
         <a href="#rid3">
          3,4
         </a>
         ]. Nonconventional etiologies, such as acute volume loss, hypotension, and associated surgical procedures (cardiac or spinal surgery) are more common in PION [
         <a href="#rid4">
          4-6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Nonarteritic ischemic optic neuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         NAION is the most common form of ischemic optic neuropathy. It is an idiopathic, ischemic insult of the optic nerve head characterized by acute, monocular, painless visual loss with optic disc swelling  (
         <a class="graphic graphic_picture graphicRef54510" href="/z/d/graphic/54510.html" rel="external">
          picture 3
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ]. Visual loss occurs due to poor perfusion in the circulation of the posterior ciliary artery, which supplies the optic nerve head [
         <a href="#rid8">
          8
         </a>
         ]. Patients are usually older than 50 years and often have hypertension, diabetes mellitus, and other vascular risk factors.
        </p>
        <p>
         Patients frequently notice the vision loss first upon waking up in the morning [
         <a href="#rid9">
          9
         </a>
         ]. There is usually decreased visual acuity and an altitudinal visual field defect. The disc appears swollen and may have splinter hemorrhages  (
         <a class="graphic graphic_picture graphicRef54510" href="/z/d/graphic/54510.html" rel="external">
          picture 3
         </a>
         ). The cup of the involved disc is typically small. If the fellow eye also has a small cup, it is considered to be at risk for future ischemic events. Magnetic resonance imaging (MRI) usually does not show enhancement or signal abnormality in the optic nerve. This is in contrast to optic neuritis, which almost always produces an MRI abnormality [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The prognosis for visual recovery is relatively poor (in contrast to optic neuritis). There is no effective treatment; optic nerve decompression is not effective [
         <a href="#rid11">
          11,12
         </a>
         ]. Recurrent events in the same eye are very rare. The cumulative risk of vision loss in the opposite eye is 14.7 percent over the next five years [
         <a href="#rid13">
          13
         </a>
         ]. There is usually an interval of several months or years between these events. Involvement of both eyes in rapid succession strongly suggests arteritis. There is no evidence that antiplatelet therapy reduces the risk of contralateral involvement; however, most patients are treated with antiplatelet therapy on the basis of their underlying vascular risk factors.
        </p>
        <p>
         NAION is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5233.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Epidemiology, pathogenesis, and etiologies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5256.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Clinical features and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5234.html" rel="external">
          "Nonarteritic anterior ischemic optic neuropathy: Prognosis and treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5232.html" rel="external">
          "Posterior ischemic optic neuropathy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Arteritic ischemic optic neuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arteritic anterior ischemic optic neuropathy occurs primarily in patients older than 70 years and is usually due to giant cell arteritis (GCA). GCA has a significant association with polymyalgia rheumatica, a constellation of symptoms that includes jaw claudication, proximal myalgias and arthralgias, scalp tenderness, headache, and fatigue along with a significantly elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
        </p>
        <p>
         Funduscopic examination demonstrates a pale, swollen disc, peripapillary hemorrhages, branch or central retinal artery occlusions, or cotton wool spots. Temporal artery biopsy is the gold standard for diagnosis, but treatment with corticosteroids should not be delayed pending biopsy or results [
         <a href="#rid8">
          8
         </a>
         ]. Thrombocytosis has been associated with a higher risk of permanent vision loss in patients with GCA [
         <a href="#rid14">
          14
         </a>
         ]. Binocular involvement occurs in a third of cases, often within the first day.
        </p>
        <p>
         This topic is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">
          "Clinical manifestations of giant cell arteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8234.html" rel="external">
          "Pathogenesis of giant cell arteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8242.html" rel="external">
          "Diagnosis of giant cell arteritis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8240.html" rel="external">
          "Treatment of giant cell arteritis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Optic neuritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic neuritis is an inflammatory, demyelinating condition that is highly associated with multiple sclerosis (MS), occurring in 50 percent of individuals at some course of their illness [
         <a href="#rid15">
          15-17
         </a>
         ].
        </p>
        <p>
         Patients typically present with acute, often painful visual loss, which is usually monocular. Individuals are typically between the ages of 18 and 40 years [
         <a href="#rid15">
          15
         </a>
         ]. Symptoms develop over a few to several days, reaching maximum severity within two weeks [
         <a href="#rid18">
          18
         </a>
         ]. Most cases (two-thirds) are retrobulbar with a normal fundus appearance  (
         <a class="graphic graphic_picture graphicRef66013" href="/z/d/graphic/66013.html" rel="external">
          picture 1
         </a>
         ), while one-third have papillitis on presentation  (
         <a class="graphic graphic_picture graphicRef50320" href="/z/d/graphic/50320.html" rel="external">
          picture 2
         </a>
         ). Gadolinium-enhanced MRI demonstrates optic nerve inflammation in 95 percent of patients  (
         <a class="graphic graphic_picture graphicRef50320" href="/z/d/graphic/50320.html" rel="external">
          picture 2
         </a>
         ) [
         <a href="#rid19">
          19
         </a>
         ]. Visual recovery is common and often complete; most patients achieve better than 20/40 vision at one year [
         <a href="#rid18">
          18
         </a>
         ]. Visual recovery is less likely, but still common in those with more severe visual loss at presentation. The clinical features and diagnosis of optic neuritis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5251.html" rel="external">
          "Optic neuritis: Pathophysiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
         Final visual outcomes are not influenced by treatment, but recovery can be hastened by intravenous
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         [
         <a href="#rid20">
          20
         </a>
         ]. Oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         therapy is not recommended, because of increased risk of recurrent optic neuritis seen in one treatment trial. Patients at high risk for MS, assessed on the basis of MRI, may benefit from immunomodulatory therapy. The prognosis and treatment of optic neuritis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5252.html" rel="external">
          "Optic neuritis: Prognosis and treatment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic neuritis may complicate meningitis or encephalitis of any cause either as a direct effect of the infectious organism or from a secondary vasculitis [
         <a href="#rid21">
          21
         </a>
         ]. West Nile virus in particular has been reported to produce optic neuritis in association with meningitis [
         <a href="#rid22">
          22,23
         </a>
         ]. Typically, in these conditions, other symptoms and signs of underlying infection, as well as MRI and cerebrospinal fluid (CSF) findings, point to the underlying cause. When the meningitis is more indolent, as with some cases of tuberculosis and cryptococcus, optic nerve involvement may be a primary manifestation [
         <a href="#rid24">
          24-26
         </a>
         ].
        </p>
        <p>
         Acute viral infections, as well as cat scratch disease and toxoplasmosis and others, can cause an isolated infection of the eye. These typically produce inflammation of the retina along with the optic disc, so-called neuroretinitis [
         <a href="#rid27">
          27-31
         </a>
         ]. Funduscopic examination usually reveals macular edema, in addition to optic disk swelling. Macular exudates form within days, often in a star-shaped pattern, "macular star." This finding helps to distinguish neuroretinitis from optic neuritis. Systemic antibiotics when appropriate and corticosteroids have been reported to produce improvement. (See
         <a class="medical medical_review" href="/z/d/html/5530.html" rel="external">
          "Treatment of cat scratch disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5699.html" rel="external">
          "Toxoplasmosis: Ocular disease"
         </a>
         .)
        </p>
        <p>
         Syphilitic optic neuritis may be monocular or binocular and is associated with vitreal inflammation, a feature that helps to distinguish this from optic neuritis [
         <a href="#rid31">
          31,32
         </a>
         ]. Antibiotic therapy is associated with recovery, but patients may relapse (see
         <a class="medical medical_review" href="/z/d/html/7599.html" rel="external">
          "Neurosyphilis"
         </a>
         ). Lyme disease is an uncertain cause of retrobulbar optic neuritis but may cause papillitis [
         <a href="#rid33">
          33,34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h2">
          Inflammatory optic neuropathies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammatory optic neuropathies may be due to parainfectious causes, systemic connective tissue disease, and other local or systemic inflammatory conditions.
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Parainfectious
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postviral optic neuritis has been associated with measles, mumps, chickenpox, influenza, and Epstein-Barr virus, typically following the clinical infection by one to three weeks [
         <a href="#rid35">
          35
         </a>
         ]. More common in children than adults and more frequently bilateral than optic neuritis, an immune-mediated process is likely. Papillitis, frequently with retinitis, is common, and there may also be a meningoencephalitis with typical MRI and CSF changes. Visual recovery is usually excellent, even with no treatment. Corticosteroids may or may not hasten recovery, but this treatment is reasonable to consider, particularly in cases of bilateral, severe visual loss. Some consider this a forme fruste of acute disseminated encephalomyelitis. (See
         <a class="medical medical_review" href="/z/d/html/6184.html" rel="external">
          "Acute disseminated encephalomyelitis (ADEM) in children: Pathogenesis, clinical features, and diagnosis", section on 'Clinical features'
         </a>
         .)
        </p>
        <p>
         While there are many case reports of optic neuritis occurring as a postvaccination phenomenon, case-control studies have not confirmed an association between vaccines and optic neuritis or other demyelinating diseases in adults [
         <a href="#rid36">
          36
         </a>
         ].
        </p>
        <p>
         Bilateral optic neuritis can also occur in the Guillain-Barré syndrome [
         <a href="#rid37">
          37
         </a>
         ]. Papillitis is common in this setting. Published case reports frequently report an antecedent infection with mycoplasma pneumoniae and recovery with treatment of Guillain-Barré syndrome [
         <a href="#rid38">
          38,39
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5172.html" rel="external">
          "Guillain-Barré syndrome in adults: Treatment and prognosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Sarcoidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic neuropathy occurs in approximately 5 percent of patients with sarcoidosis and may be the initial manifestation [
         <a href="#rid10">
          10,40
         </a>
         ]. Clinical features are similar to optic neuritis. Bilateral involvement has been reported in 24 to 64 percent [
         <a href="#rid40">
          40,41
         </a>
         ]. The optic disc may have a nodular appearance, representing the granulomatous infiltration. MRI can demonstrate signal abnormality and nerve thickening with gadolinium enhancement that may be generalized, nodular, or meningeal. Other cerebral parenchymal lesions and more widespread meningitis may also be seen on MRI. Visual recovery often follows corticosteroid treatment, but some patients have permanent vision loss [
         <a href="#rid40">
          40
         </a>
         ]. Relapsing vision loss following a short course of corticosteroids for presumed optic neuritis is a clue to this disorder. (See
         <a class="medical medical_review" href="/z/d/html/4834.html" rel="external">
          "Neurologic sarcoidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H544793929">
         <span class="h3">
          Chronic relapsing inflammatory optic neuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic relapsing inflammatory optic neuropathy (CRION) is a rare, relapsing autoimmune optic neuritis in which no other known systemic disease can be found; these patients do not have sarcoidosis, lupus, MS, neuromyelitis optica (NMO), or other cause [
         <a href="#rid42">
          42,43
         </a>
         ]. On first presentation, the clinical features are those of optic neuritis, including enhancement of the optic nerve on MRI. In contrast to patients with optic neuritis, tapering glucocorticoid therapy leads to a clinical relapse. In order to stay in remission, patients with CRION require chronic immunosuppression with steroid-sparing agents such
         <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">
          azathioprine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         , or intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG). Diagnostic work-up should exclude other systemic, metabolic, toxic, or paraneoplastic causes of optic neuropathy, including serum myelin oligodendrocyte glycoprotein (MOG) and aquaporin 4 (AQP4) immunoglobulin G (IgG) antibody tests.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Systemic autoimmune disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optic neuritis is a rare manifestation of other systemic inflammatory or connective tissue disease and usually occurs in the setting of an established diagnosis [
         <a href="#rid44">
          44
         </a>
         ]. The mechanisms and therefore presentations of optic nerve involvement vary with the disorder. In some cases, optic neuritis may represent shared coincidence of autoimmune diseases, rather than a primary manifestation of the systemic disease.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Systemic lupus erythematosus (SLE). Optic nerve involvement occurs in approximately 1 percent of patients with SLE and may be due to vasculitis or to thrombosis secondary to antiphospholipid antibody syndrome [
         <a href="#rid44">
          44-46
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sjögren's disease (SjD). Optic neuritis may be the presenting symptom of this disorder [
         <a href="#rid44">
          44,47
         </a>
         ]. In one eight-year, retrospective review of 82 patients with SjD, 16 percent had optic neuritis [
         <a href="#rid48">
          48
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Granulomatosis with polyangiitis. Extension of inflammation in the sinus and parasinus areas can produce optic neuritis, usually with other orbital signs [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Behçet syndrome. Despite producing severe meningitis and uveitis, optic neuritis is a rare complication in this disorder [
         <a href="#rid44">
          44,50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inflammatory bowel disease. The higher than expected incidence of optic neuritis in these disorders may reflect coincidence of autoimmune diseases [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Paraneoplastic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Paraneoplastic optic neuritis has been described in a few reports, usually in association with paraneoplastic encephalomyelitis or retinitis and small cell lung cancer [
         <a href="#rid53">
          53-55
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h2">
          Compressive optic neuropathies
         </span>
         <span class="headingEndMark">
          —
         </span>
         In this category of disorders, gradual vision loss is the more usual presentation, as expected with slowly growing lesions; however, the presentation can be acute. Pain is variable. MRI of the brain and orbits will confirm or rule out diagnoses associated with compressive optic neuropathy. Corticosteroid therapy may produce early visual improvement due to reduction in edema, and therefore may be misleading as to the underlying etiology.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Neoplasia
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of tumors can produce optic nerve compression. Sellar and parasellar masses (craniopharyngioma, meningioma, or pituitary adenoma), optic nerve sheath meningiomas, and metastatic lesions are included in the differential diagnosis.
        </p>
        <p>
         Tumors, particularly optic nerve gliomas associated with neurofibromatosis, but also lymphoma and other hematologic malignancies, can also infiltrate rather than compress the optic nerve [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Others
         </span>
         <span class="headingEndMark">
          —
         </span>
         The optic nerve can be compressed by other, non-neoplastic processes within the orbit or subarachnoid space. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dysthyroid ophthalmopathy (see
         <a class="medical medical_review" href="/z/d/html/7825.html" rel="external">
          "Clinical features and diagnosis of thyroid eye disease"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Carotid-ophthalmic artery aneurysms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abscess
        </p>
        <p>
        </p>
        <p>
         Idiopathic intracranial hypertension or pseudotumor cerebri can lead to a bilateral optic neuropathy. Patients usually present with headache sometimes accompanied by horizontal diplopia. Vision loss may be slowly progressive or may appear abruptly. Funduscopic examination reveals papilledema. Visual field defects are characterized by enlarged blind spot and/or generalized constriction. If untreated, patients may become blind. (See
         <a class="medical medical_review" href="/z/d/html/5257.html" rel="external">
          "Idiopathic intracranial hypertension (pseudotumor cerebri): Clinical features and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h2">
          Genetic causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two of the more common of the genetic causes of optic neuropathy are Leber hereditary optic neuropathy and Kjer's disease.
        </p>
        <p class="headingAnchor" id="H309502">
         <span class="h3">
          Leber hereditary optic neuropathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         In this disorder, vision loss is subacute and painless, with sequential involvement of both eyes over a period of weeks to months.
        </p>
        <p>
         This disorder affects young males predominantly (80 to 90 percent of patients) and is inherited through a mitochondrial DNA mutation. Three mutations at positions 11,778, 3460, and 14,484 are responsible for greater than 90 percent of all cases of Leber [
         <a href="#rid58">
          58
         </a>
         ]. These genes are involved in complex I of the mitochondrial respiratory chain [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Funduscopic examination usually shows circumpapillary telangiectasia, but up to one-third of patients can have a normal appearing disc. Nerve fiber layer swelling around the disc can be seen, although
         <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">
          fluorescein
         </a>
         angiography does not show leakage from the disc or papillary area [
         <a href="#rid60">
          60
         </a>
         ]. Central vision is affected more severely. MRI can show signal abnormality in the optic nerves, but enhancement usually does not occur [
         <a href="#rid10">
          10,61,62
         </a>
         ]. Prognosis for recovery varies depending on the mutation [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         This topic is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6226.html" rel="external">
          "Neuropathies associated with hereditary disorders", section on 'Leber hereditary optic neuropathy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H309509">
         <span class="h3">
          Kjer-type autosomal dominant optic atrophy
         </span>
         <span class="headingEndMark">
          —
         </span>
         This entity primarily affects children in the first decade of life with slowly progressive, bilateral loss of vision. As with other optic neuropathies, there is pallor of the optic disc, cecocentral scotoma, and color vision loss. The
         <em>
          OPA1
         </em>
         gene located on chromosome 3q28 has been implicated in the majority of patients with dominant optic atrophy [
         <a href="#rid63">
          63,64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h2">
          Toxic and metabolic causes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Toxic metabolic causes of optic neuropathy include an extensive list of possible agents. Typically, involvement is bilateral; onset may be abrupt or slowly progressive.
        </p>
        <p class="headingAnchor" id="H20">
         <span class="h3">
          Drugs and toxins
         </span>
         <span class="headingEndMark">
          —
         </span>
         A number of toxins and drugs have been associated with optic neuropathy  (
         <a class="graphic graphic_table graphicRef57497" href="/z/d/graphic/57497.html" rel="external">
          table 3
         </a>
         ). In many cases of toxin exposure, the visual loss is severe and permanent [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
         Patients experiencing vision loss as an adverse effect of medications can have limited impairment if the vision loss is detected early and the drug discontinued [
         <a href="#rid65">
          65
         </a>
         ]. Most of these medications are believed to have direct toxic effects on the optic nerve [
         <a href="#rid66">
          66
         </a>
         ]. Of these, the risks associated with
         <a class="drug drug_general" data-topicid="9430" href="/z/d/drug information/9430.html" rel="external">
          ethambutol
         </a>
         are perhaps best characterized [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/478.html" rel="external">
          "Ethambutol: An overview", section on 'Visual changes'
         </a>
         .)
        </p>
        <p>
         Other medications are believed to affect the optic nerve indirectly through other mechanisms:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">
          Infliximab
         </a>
         is believed to cause an autoimmune optic neuritis [
         <a href="#rid68">
          68,69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7970.html" rel="external">
          "Tumor necrosis factor-alpha inhibitors: An overview of adverse effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several cases of severe optic neuropathy in patients treated with
         <a class="drug drug_general" data-topicid="8683" href="/z/d/drug information/8683.html" rel="external">
          bevacizumab
         </a>
         for glioblastoma were summarized in a 2009 report [
         <a href="#rid70">
          70
         </a>
         ]. The mechanism is uncertain; however, vascular etiologies, drug-induced sensitivity to radiation, and direct toxic effects are possible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          Sildenafil
         </a>
         and other drugs prescribed for erectile dysfunction have been reported to produce a NAION [
         <a href="#rid71">
          71,72
         </a>
         ]. An association is not proven; however, the close temporal proximity of drug administration and symptoms in these cases suggests cause and effect. (See
         <a class="local">
          'Ischemic optic neuropathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">
          Amiodarone
         </a>
         's association with optic neuropathy remains somewhat controversial [
         <a href="#rid73">
          73,74
         </a>
         ]. Some cases appear indistinguishable from NAION. Other reported cases of a more insidious onset with slow progression and simultaneous bilateral involvement suggest a more direct toxic effect. (See
         <a class="medical medical_review" href="/z/d/html/931.html" rel="external">
          "Amiodarone: Adverse effects, potential toxicities, and approach to monitoring", section on 'Optic neuropathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Several cases of optic neuritis have been reported to be associated with immune checkpoint inhibitors. This class of medications is used in oncology for the treatment of a variety of cancers. Because of the mechanism of action of these drugs, it is presumed that the optic neuritis triggered by these medications is autoimmune in nature and possibly responsive to treatment with steroids [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21">
         <span class="h3">
          Nutritional deficiencies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nutritional deficiencies are presumed to have played a role in endemic optic neuropathy reported under conditions of deprivation, such as in prisoners of war (eg, Cuba in the 1990s, southeast Asia during World War II) [
         <a href="#rid76">
          76-78
         </a>
         ]. An endemic optic neuropathy in Tanzania described in several reports from 1988 through 2013 has also been attributed to nutritional deficiencies [
         <a href="#rid79">
          79-82
         </a>
         ].
        </p>
        <p>
         Specific deficiencies of vitamins B12, B1, and folate have been implicated. Most nutritional optic neuropathies appear to be exacerbated by tobacco and possibly alcoholism (tobacco-alcohol amblyopia) [
         <a href="#rid83">
          83
         </a>
         ]. Vision loss may be unilateral or bilateral, and can have an acute, subacute, or slowly progressive presentation [
         <a href="#rid78">
          78
         </a>
         ]. MRI is typically normal [
         <a href="#rid10">
          10,84
         </a>
         ]. Early vitamin supplementation and/or smoking cessation have been anecdotally associated with visual recovery, but this is not guaranteed.
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h3">
          Radiation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Radiation-induced damage of the optic nerves and/or chiasm can occur 6 to 24 months after radiation therapy, usually for nasal carcinoma. In one series of 219 patients who received radiotherapy for carcinomas of the nasal or paranasal region, retinopathy occurred in seven, optic neuropathy with blindness in eight, and chiasm damage with bilateral visual impairment in one [
         <a href="#rid85">
          85
         </a>
         ]. These complications are rare with doses of radiation less than 50 Gy. The vision loss is usually slowly progressive, and there is no treatment proven to be effective. MRI may show signal abnormality with enhancement in the optic nerve. (See
         <a class="medical medical_review" href="/z/d/html/91670.html" rel="external">
          "Delayed complications of cranial irradiation", section on 'Optic neuropathy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Trauma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Closed head injury may damage the optic nerve, usually affecting the intraorbital or intracanalicular segments. The mechanism may be contusion or hemorrhage; rarely, the optic nerve is transected or avulsed [
         <a href="#rid86">
          86,87
         </a>
         ]. In the latter case, vision does not improve. Otherwise, the prognosis depends upon the extent of the injury; approximately half of patients recover. Imaging studies and an ophthalmologic consult are indicated to evaluate for pathologies (optic nerve sheath hematoma, orbital hemorrhage) that require surgery. Surgical decompression and high-dose corticosteroids are sometimes used but are not of proven benefit [
         <a href="#rid88">
          88-90
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H348622667">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/83437.html" rel="external">
          "Patient education: Optic neuritis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An optic nerve lesion produces visual loss, usually monocular. Other clinical features can include dyschromatopsia, pain (especially with eye movement), and papillitis, depending on the etiology. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The potential causes of optic neuropathy are diverse  (
         <a class="graphic graphic_table graphicRef75945" href="/z/d/graphic/75945.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Etiologies'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Optic neuritis is the most common cause of optic nerve disease in younger adults, while ischemic optic neuropathy is the most common etiology in older patients. (See
         <a class="local">
          'Ischemic optic neuropathy'
         </a>
         above and
         <a class="local">
          'Optic neuritis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated demographic and clinical features, including age and gender; the presence of pain, papillitis, or bilateral involvement; and the acuity of presentation, are useful to identify the most likely etiology  (
         <a class="graphic graphic_table graphicRef51786" href="/z/d/graphic/51786.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Giant cell arteritis (GCA) should always be considered in the differential diagnosis of optic neuropathy in individuals over 50 years because of its potential for permanent vision loss, which can be prevented by prompt intervention. (See
         <a class="local">
          'Arteritic ischemic optic neuropathy'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Glaser JS. Topical diagnosis: Prechiasmal visual pathways. In: Neuro-ophthalmology, Glaser JS (Ed), JB Lippincott, Philadelphia 1990. p.83.
         </li>
         <li class="breakAll">
          Sadun AA. The afferent visual system: Anatomy and Physiology. In: Ophthalmology, 2nd ed, Yanoff M, Duker JS (Eds), Mosby, St. Louis 2004. p.186.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS. Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management. Eye (Lond) 2004; 18:1188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadda SR, Nee M, Miller NR, et al. Clinical spectrum of posterior ischemic optic neuropathy. Am J Ophthalmol 2001; 132:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buono LM, Foroozan R. Perioperative posterior ischemic optic neuropathy: review of the literature. Surv Ophthalmol 2005; 50:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunker S, Hsu HY, Sebag J, Sadun AA. Perioperative risk factors for posterior ischemic optic neuropathy. J Am Coll Surg 2002; 194:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swartz NG, Beck RW, Savino PJ, et al. Pain in anterior ischemic optic neuropathy. J Neuroophthalmol 1995; 15:9.
          </a>
         </li>
         <li class="breakAll">
          Liu GT. Visual loss: optic neuropathies. In: Neuro-Ophthalmology: Diagnosis and Management, Liu GT, Volpe NJ, Galetta SL (Eds), WB Saunders, Philadelphia 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arnold AC. Ischemic optic neuropathies. Ophthalmol Clin North Am 2001; 14:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gass A, Moseley IF. The contribution of magnetic resonance imaging in the differential diagnosis of optic nerve damage. J Neurol Sci 2000; 172 Suppl 1:S17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group. JAMA 1995; 273:625.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dickersin K, Manheimer E, Li T. Surgery for nonarteritic anterior ischemic optic neuropathy. Cochrane Database Syst Rev 2006; :CD001538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman NJ, Scherer R, Langenberg P, et al. The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study. Am J Ophthalmol 2002; 134:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients. Am J Med 2001; 111:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med 2006; 354:1273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foroozan R, Buono LM, Savino PJ, Sergott RC. Acute demyelinating optic neuritis. Curr Opin Ophthalmol 2002; 13:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frohman EM, Frohman TC, Zee DS, et al. The neuro-ophthalmology of multiple sclerosis. Lancet Neurol 2005; 4:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group. Arch Ophthalmol 1991; 109:1673.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rizzo JF 3rd, Andreoli CM, Rabinov JD. Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002; 109:1679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992; 326:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AG, Brazis PW. Systemic infections of neuro-ophthalmic significance. Ophthalmol Clin North Am 2004; 17:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anninger WV, Lomeo MD, Dingle J, et al. West Nile virus-associated optic neuritis and chorioretinitis. Am J Ophthalmol 2003; 136:1183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan CK, Limstrom SA, Tarasewicz DG, Lin SG. Ocular features of west nile virus infection in North America: a study of 14 eyes. Ophthalmology 2006; 113:1539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golnik KC. Infectious optic neuropathy. Semin Ophthalmol 2002; 17:11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesh P, Garg SP, Verma L, et al. Combined optic neuropathy and central retinal artery occlusion in miliary tuberculosis. Retina 2001; 21:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rex JH, Larsen RA, Dismukes WE, et al. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine (Baltimore) 1993; 72:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukushima A, Yasuoka M, Tsukahara M, Ueno H. A case of cat scratch disease neuroretinitis confirmed by polymerase chain reaction. Jpn J Ophthalmol 2003; 47:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilden DH, Mahalingam R, Cohrs RJ, Tyler KL. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol 2007; 3:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Küçükerdönmez C, Akova YA, Yilmaz G. Ocular toxoplasmosis presenting as neuroretinitis: report of two cases. Ocul Immunol Inflamm 2002; 10:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benz MS, Glaser JS, Davis JL. Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids. Am J Ophthalmol 2003; 135:551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ray S, Gragoudas E. Neuroretinitis. Int Ophthalmol Clin 2001; 41:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith GT, Goldmeier D, Migdal C. Neurosyphilis with optic neuritis: an update. Postgrad Med J 2006; 82:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sibony P, Halperin J, Coyle PK, Patel K. Reactive Lyme serology in optic neuritis. J Neuroophthalmol 2005; 25:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krim E, Guehl D, Burbaud P, Lagueny A. Retrobulbar optic neuritis: a complication of Lyme disease? J Neurol Neurosurg Psychiatry 2007; 78:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farris BK, Pickard DJ. Bilateral postinfectious optic neuritis and intravenous steroid therapy in children. Ophthalmology 1990; 97:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeStefano F, Verstraeten T, Jackson LA, et al. Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003; 60:504.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Evliyaoglu F, Karadag R, Burakgazi AZ. Ocular neuropathy in peripheral neuropathies. Muscle Nerve 2012; 46:681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ginestal RC, Plaza JF, Callejo JM, et al. Bilateral optic neuritis and Guillain-Barré syndrome following an acute Mycoplasma pneumoniae infection. J Neurol 2004; 251:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfausler B, Engelhardt K, Kampfl A, et al. Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature. Eur J Neurol 2002; 9:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pawate S, Moses H, Sriram S. Presentations and outcomes of neurosarcoidosis: a study of 54 cases. QJM 2009; 102:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joseph FG, Scolding NJ. Neurosarcoidosis: a study of 30 new cases. J Neurol Neurosurg Psychiatry 2009; 80:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidd D, Burton B, Plant GT, Graham EM. Chronic relapsing inflammatory optic neuropathy (CRION). Brain 2003; 126:276.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Petzold A, Plant GT. Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 2014; 261:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theodoridou A, Settas L. Demyelination in rheumatic diseases. J Neurol Neurosurg Psychiatry 2006; 77:290.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabs DA, Miller NR, Newman SA, et al. Optic neuropathy in systemic lupus erythematosus. Arch Ophthalmol 1986; 104:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giorgi D, Balacco Gabrieli C. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Clin Rheumatol 1999; 18:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rabadi MH, Kundi S, Brett D, Padmanabhan R. Neurological pictures. Primary Sjögren syndrome presenting as neuromyelitis optica. J Neurol Neurosurg Psychiatry 2010; 81:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delalande S, de Seze J, Fauchais AL, et al. Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients. Medicine (Baltimore) 2004; 83:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monteiro ML, Borges WI, do Val Ferreira Ramos C, et al. Bilateral optic neuritis in wegener granulomatosis. J Neuroophthalmol 2005; 25:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kansu T, Kirkali P, Kansu E, Zileli T. Optic neuropathy in Behçet's disease. J Clin Neuroophthalmol 1989; 9:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ernst BB, Lowder CY, Meisler DM, Gutman FA. Posterior segment manifestations of inflammatory bowel disease. Ophthalmology 1991; 98:1272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pillay N, Gilbert JJ, Ebers GC, Brown JD. Internuclear ophthalmoplegia and "optic neuritis": paraneoplastic effects of bronchial carcinoma. Neurology 1984; 34:788.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross SA, Salomao DR, Parisi JE, et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann Neurol 2003; 54:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee AG, Tang RA, Roberts D, et al. Primary central nervous system lymphoma involving the optic chiasm in AIDS. J Neuroophthalmol 2001; 21:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008; 71:1355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Howell N. LHON and other optic nerve atrophies: the mitochondrial connection. Dev Ophthalmol 2003; 37:94.
          </a>
         </li>
         <li class="breakAll">
          Miller NR, Newman NJ, Biousse V, Kerrison JB. Walsh and Hoyt's Clinical Neuro-ophthalmology, Lippincott, Williams and Wilkins, Philadelphia 2005.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith JL, Hoyt WF, Susac JO. Ocular fundus in acute Leber optic neuropathy. Arch Ophthalmol 1973; 90:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermode AG, Moseley IF, Kendall BE, et al. Magnetic resonance imaging in Leber's optic neuropathy. J Neurol Neurosurg Psychiatry 1989; 52:671.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamirel C, Cassereau J, Cochereau I, et al. Papilloedema and MRI enhancement of the prechiasmal optic nerve at the acute stage of Leber hereditary optic neuropathy. J Neurol Neurosurg Psychiatry 2010; 81:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Votruba M, Thiselton D, Bhattacharya SS. Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy. Br J Ophthalmol 2003; 87:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander C, Votruba M, Pesch UE, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 2000; 26:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerrison JB. Optic neuropathies caused by toxins and adverse drug reactions. Ophthalmol Clin North Am 2004; 17:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McKinley SH, Foroozan R. Optic neuropathy associated with linezolid treatment. J Neuroophthalmol 2005; 25:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melamud A, Kosmorsky GS, Lee MS. Ocular ethambutol toxicity. Mayo Clin Proc 2003; 78:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ten Tusscher MP, Jacobs PJ, Busch MJ, et al. Bilateral anterior toxic optic neuropathy and the use of infliximab. BMJ 2003; 326:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Foroozan R, Buono LM, Sergott RC, Savino PJ. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 2002; 120:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman JH, Aregawi DG, Lai A, et al. Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 2009; 73:1924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hayreh SS. Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship? J Neuroophthalmol 2005; 25:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pomeranz HD, Bhavsar AR. Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases. J Neuroophthalmol 2005; 25:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen D, Hedges TR. Amiodarone optic neuropathy--review. Semin Ophthalmol 2003; 18:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagra PK, Foroozan R, Savino PJ, et al. Amiodarone induced optic neuropathy. Br J Ophthalmol 2003; 87:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Francis JH, Jaben K, Santomasso BD, et al. Immune Checkpoint Inhibitor-Associated Optic Neuritis. Ophthalmology 2020; 127:1585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cuba Neuropathy Field Investigation Team. Epidemic optic neuropathy in Cuba--clinical characterization and risk factors. N Engl J Med 1995; 333:1176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newman NJ. Optic neuropathy. Neurology 1996; 46:315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadun AA. Metabolic optic neuropathies. Semin Ophthalmol 2002; 17:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kisimbi J, Shalchi Z, Mahroo OA, et al. Macular spectral domain optical coherence tomography findings in Tanzanian endemic optic neuropathy. Brain 2013; 136:3418.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Plant GT, Mtanda AT, Arden GB, Johnson GJ. An epidemic of optic neuropathy in Tanzania: characterization of the visual disorder and associated peripheral neuropathy. J Neurol Sci 1997; 145:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman RJ, Wedner S, Bowman RF, et al. Optic neuropathy endemic in secondary school children in Dar es Salaam, Tanzania. Br J Ophthalmol 2010; 94:146.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolin PJ, Mohamed AA, Plant GT. Epidemic of bilateral optic neuropathy in Dar es Salaam, Tanzania. N Engl J Med 1998; 338:1547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solberg Y, Rosner M, Belkin M. The association between cigarette smoking and ocular diseases. Surv Ophthalmol 1998; 42:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kermode AG, Plant GT, Miller DH, et al. Tobacco-alcohol amblyopia: magnetic resonance imaging findings. J Neurol Neurosurg Psychiatry 1989; 52:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jiang GL, Tucker SL, Guttenberger R, et al. Radiation-induced injury to the visual pathway. Radiother Oncol 1994; 30:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simsek T, Simsek E, Ilhan B, et al. Traumatic optic nerve avulsion. J Pediatr Ophthalmol Strabismus 2006; 43:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarkies N. Traumatic optic neuropathy. Eye (Lond) 2004; 18:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin LA, Beck RW, Joseph MP, et al. The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study. Ophthalmology 1999; 106:1268.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinsapir KD. Treatment of traumatic optic neuropathy with high-dose corticosteroid. J Neuroophthalmol 2006; 26:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu-Wai-Man P, Griffiths PG. Steroids for traumatic optic neuropathy. Cochrane Database Syst Rev 2013; :CD006032.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5244 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Glaser JS. Topical diagnosis: Prechiasmal visual pathways. In: Neuro-ophthalmology, Glaser JS (Ed), JB Lippincott, Philadelphia 1990. p.83.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Sadun AA. The afferent visual system: Anatomy and Physiology. In: Ophthalmology, 2nd ed, Yanoff M, Duker JS (Eds), Mosby, St. Louis 2004. p.186.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15534605" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Posterior ischaemic optic neuropathy: clinical features, pathogenesis, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11704036" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical spectrum of posterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15621075" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Perioperative posterior ischemic optic neuropathy: review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12081060" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Perioperative risk factors for posterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7780575" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Pain in anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7780575" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pain in anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11370574" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Ischemic optic neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10606800" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The contribution of magnetic resonance imaging in the differential diagnosis of optic nerve damage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7844872" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Optic nerve decompression surgery for nonarteritic anterior ischemic optic neuropathy (NAION) is not effective and may be harmful. The Ischemic Optic Neuropathy Decompression Trial Research Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16437435" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Surgery for nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12208242" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The fellow eye in NAION: report from the ischemic optic neuropathy decompression trial follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11530032" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Risk factors for visual loss in giant cell (temporal) arteritis: a prospective study of 174 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16554529" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Clinical practice. Optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441840" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Acute demyelinating optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15664543" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The neuro-ophthalmology of multiple sclerosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1841573" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The clinical profile of optic neuritis. Experience of the Optic Neuritis Treatment Trial. Optic Neuritis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12208717" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Use of magnetic resonance imaging to differentiate optic neuritis and nonarteritic anterior ischemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1734247" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337196" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Systemic infections of neuro-ophthalmic significance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14644244" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : West Nile virus-associated optic neuritis and chorioretinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16860390" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Ocular features of west nile virus infection in North America: a study of 14 eyes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15513450" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Infectious optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11508887" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Combined optic neuropathy and central retinal artery occlusion in miliary tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8341139" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Catastrophic visual loss due to Cryptococcus neoformans meningitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12842212" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : A case of cat scratch disease neuroretinitis confirmed by polymerase chain reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17279082" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Herpesvirus infections of the nervous system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12789599" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Ocular toxoplasmosis presenting as neuroretinitis: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12654381" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Progressive outer retinal necrosis in immunocompetent patients treated initially for optic neuropathy with systemic corticosteroids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11198149" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Neuroretinitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16397078" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Neurosyphilis with optic neuritis: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15937426" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Reactive Lyme serology in optic neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18024698" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Retrobulbar optic neuritis: a complication of Lyme disease?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2336272" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Bilateral postinfectious optic neuritis and intravenous steroid therapy in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12707063" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Vaccinations and risk of central nervous system demyelinating diseases in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23055310" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Ocular neuropathy in peripheral neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15311361" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Bilateral optic neuritis and Guillain-Barrésyndrome following an acute Mycoplasma pneumoniae infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11784383" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19383611" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Presentations and outcomes of neurosarcoidosis: a study of 54 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18977817" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Neurosarcoidosis: a study of 30 new cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12538397" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Chronic relapsing inflammatory optic neuropathy (CRION).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23700317" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16484634" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Demyelination in rheumatic diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3954662" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Optic neuropathy in systemic lupus erythematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10357117" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20145030" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Neurological pictures. Primary Sjögren syndrome presenting as neuromyelitis optica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15342972" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Neurologic manifestations in primary Sjögren syndrome: a study of 82 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15756129" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Bilateral optic neuritis in wegener granulomatosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2531168" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Optic neuropathy in Behçet's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16143121" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Increased risk for demyelinating diseases in patients with inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1923366" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Posterior segment manifestations of inflammatory bowel disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6539443" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Internuclear ophthalmoplegia and "optic neuritis": paraneoplastic effects of bronchial carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11220734" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12838519" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11450910" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Primary central nervous system lymphoma involving the optic chiasm in AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18936428" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12876832" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : LHON and other optic nerve atrophies: the mitochondrial connection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12876832" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : LHON and other optic nerve atrophies: the mitochondrial connection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4746084" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Ocular fundus in acute Leber optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2732742" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Magnetic resonance imaging in Leber's optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20460595" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Papilloedema and MRI enhancement of the prechiasmal optic nerve at the acute stage of Leber hereditary optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12488262" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Optic disc morphology of patients with OPA1 autosomal dominant optic atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11017080" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337202" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Optic neuropathies caused by toxins and adverse drug reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15756127" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Optic neuropathy associated with linezolid treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14601701" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Ocular ethambutol toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12637403" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Bilateral anterior toxic optic neuropathy and the use of infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12096976" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Retrobulbar optic neuritis associated with infliximab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19949039" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Optic neuropathy in patients with glioblastoma receiving bevacizumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16340497" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Erectile dysfunction drugs and non-arteritic anterior ischemic optic neuropathy: is there a cause and effect relationship?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15756125" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Nonarteritic ischemic optic neuropathy developing soon after use of sildenafil (viagra): a report of seven new cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15513002" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Amiodarone optic neuropathy--review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12642303" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Amiodarone induced optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32437864" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Immune Checkpoint Inhibitor-Associated Optic Neuritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7565972" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Epidemic optic neuropathy in Cuba--clinical characterization and risk factors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8614487" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15513453" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Metabolic optic neuropathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24018312" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Macular spectral domain optical coherence tomography findings in Tanzanian endemic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9094040" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : An epidemic of optic neuropathy in Tanzania: characterization of the visual disorder and associated peripheral neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19666929" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Optic neuropathy endemic in secondary school children in Dar es Salaam, Tanzania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9599114" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Epidemic of bilateral optic neuropathy in Dar es Salaam, Tanzania.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9635902" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The association between cigarette smoking and ocular diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2614454" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Tobacco-alcohol amblyopia: magnetic resonance imaging findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8153376" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Radiation-induced injury to the visual pathway.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17162975" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Traumatic optic nerve avulsion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15534597" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Traumatic optic neuropathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10406604" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : The treatment of traumatic optic neuropathy: the International Optic Nerve Trauma Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16518171" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Treatment of traumatic optic neuropathy with high-dose corticosteroid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23771729" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Steroids for traumatic optic neuropathy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
